Finanzen von Relmada Therapeutics Inc (RLMD)RLMDRelmada Therapeutics Inc

Evaluating the bottom line, Relmada Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -55.66%, provide a clear picture of how effectively RLMD converts its operational activities into shareholder value.

In the context of the broader market, RLMD competes directly with industry leaders such as EBS and ENTA. With a market capitalization of $358.41M, it holds a leading position in the sector. When comparing efficiency, RLMD's gross margin of N/A stands against EBS's 58.56% and ENTA's 100.00%. Such benchmarking helps identify whether Relmada Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Relmada has shown a significant increase in common stock equity, rising from $9,465,539 in Q3 2025 to $206,558,323 in Q2 2026, indicating improved financial stability. However, it continues to report negative net income, with Q2 2026 showing a loss of $12,914,185.